Alprostadil for treatment of premature ejaculation

Abstract

Compositions and methods for the treatment of premature ejaculation are provided wherein a composition comprising a topical anesthetic, a shear-thinning polymeric thickener, a lipophilic component that is selected from the group consisting of an aliphatic C 1 to C 8 alcohol, an aliphatic C 8 to C 30 ester, a liquid polyol and a mixture thereof, water and a buffer system that provides a buffered pH value for the composition in the range of about 3 to about 7.4 is administered to the penile meatus.

1 - 43 . (canceled) 
     
     
         44 . A method of prolonging ejaculation latency in a patient comprising:
 administering meatally to the patient a topical composition comprising:   about 0.1 mg to about 0.5 mg by weight of a vasoactive prostaglandin selected from the group consisting of prostaglandin E 1 , a pharmaceutically acceptable salt thereof, a lower alkyl ester thereof, and a mixture thereof.   
     
     
         45 . The method of  claim 44 , wherein 0.4 percent by weight based on the weight of the composition is the vasoactive prostaglandin. 
     
     
         46 . The method of  claim 44 , wherein the amount of vasoactive prostaglandin administered is from about 0.3 mg to about 0.5 mg. 
     
     
         47 . The method of  claim 44 , wherein the amount of vasoactive prostaglandin administered is from about 0.2 mg to 0.5 mg. 
     
     
         48 . The method of  claim 44 , wherein the amount of vasoactive prostaglandin administered is about 0.2 mg to about 0.3 mg. 
     
     
         49 . The method of  claim 44 , wherein the amount of vasoactive prostaglandin administered is from about 0.1 mg to about 0.3 mg. 
     
     
         50 . The method of  claim 44 , wherein the amount of vasoactive prostaglandin administered is from about 0.1 mg to about 0.2 mg. 
     
     
         51 . The method of  claim 44 , wherein the composition further comprises about 0.1 to about 5 percent by weight based on the weight of the composition a penetration enhancer. 
     
     
         52 . The method of  claim 51 , wherein the penetration enhancer is dodecyl 2-(N,N-dimethylamino)-propionate or a pharmaceutically acceptable salt. 
     
     
         53 . The method of  claim 51 , wherein 0.4 percent by weight based on the weight of the composition is the vasoactive prostaglandin. 
     
     
         54 . The method of  claim 51 , wherein the amount of vasoactive prostaglandin administered is from about 0.3 mg to about 0.5 mg. 
     
     
         55 . The method of  claim 51 , wherein the amount of vasoactive prostaglandin administered is from about 0.2 mg to 0.5 mg. 
     
     
         56 . The method of  claim 51 , wherein the amount of vasoactive prostaglandin administered is about 0.2 mg to about 0.3 mg. 
     
     
         57 . The method of  claim 51 , wherein the amount of vasoactive prostaglandin administered is from about 0.1 mg to about 0.3 mg. 
     
     
         58 . The method of  claim 51 , wherein the amount of vasoactive prostaglandin administered is from about 0.1 mg to about 0.2 mg. 
     
     
         59 . The method of  claim 44 , wherein the composition further comprises a topical anesthetic. 
     
     
         60 . The method of  claim 59 , wherein the topical anesthetic is bupivacaine, dyclonine, or lidocaine. 
     
     
         61 . The method of  claim 59 , wherein 0.4 percent by weight based on the weight of the composition is the vasoactive prostaglandin. 
     
     
         62 . The method of  claim 59 , wherein the amount of vasoactive prostaglandin administered is from about 0.3 mg to about 0.5 mg. 
     
     
         63 . The method of  claim 59 , wherein the amount of vasoactive prostaglandin administered is from about 0.2 mg to 0.5 mg. 
     
     
         64 . The method of  claim 59 , wherein the amount of vasoactive prostaglandin administered is about 0.2 mg to about 0.3 mg. 
     
     
         65 . The method of  claim 59 , wherein the amount of vasoactive prostaglandin administered is from about 0.1 mg to about 0.3 mg. 
     
     
         66 . The method of  claim 59 , wherein the amount of vasoactive prostaglandin administered is from about 0.1 mg to about 0.2 mg.